A Nature Communications study reported that a combined bacteriophage‑antibiotic therapy successfully treated refractory peritoneal dialysis‑related peritonitis caused by multidrug‑resistant Klebsiella pneumoniae in preclinical models. The research team demonstrated synergistic bactericidal effects and improved outcomes versus monotherapy. Authors described phage selection, in vitro synergy assays, and in vivo testing that showed reduction of bacterial burden and mitigation of infection sequelae. The study highlights combination strategies to overcome phage resistance and antibiotic tolerance in severe Gram‑negative infections. The results will interest companies developing phage therapeutics, antibiotic adjuvants, and clinicians managing device‑related infections. Clinical translation will require manufacturing scale‑up, regulatory pathway clarification for phage products, and carefully designed human trials to confirm safety and efficacy.